To cure human obesity by turning fat-storing cells into fat-burning cells.
AptamiR Therapeutics, Inc. is a biotechnology company founded in 2012, focused on developing a revolutionary treatment for human obesity. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (brown-like, brite or beige). MicroRNAs are attractive drug candidates for complex diseases like obesity, as they can modulate the expression of gene networks. AptamiR is also developing drug delivery approaches that can specifically target microRNA modulators to adipose tissue.